SIMPL’HIV Wk 144 Results: Dolutegravir + Emtricitabine vs Standard Combination ART for Maintenance of Virologic Suppression

Source: CCO Official Conference Coverage: Clinical Impact of New HIV Data From AIDS 2022
Download Slideset
July 29-August 2, 2022; Montreal, Quebec
Switching from standard combination ART to DTG plus FTC was noninferior to continuing standard combination ART in virologically suppressed adults through Week 144 in this randomized clinical trial.
Format: Microsoft PowerPoint (.ppt)
File Size: 222 KB
Released: August 2, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings